Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
2019 · Leukemia · 153 citations
https://doi.org/10.1038/s41375-019-0545-2
D
Dehui Zou
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
512
Papers
3.1K
Citations
29
h-index
69
i10-index
Dehui Zou is an academic researcher from Nanjing University of Chinese Medicine. The author has contributed to research in topics: Multiple Myeloma Research and Treatments & Chronic Lymphocytic Leukemia Research & Lymphoma Diagnosis and Treatment. The author has an h-index of 29, co-authored 436 publications.
ORCID: 0000-0002-8135-4913Papers by this author
worksEfficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia
2020 · Journal of Hematology & Oncology · 107 citations
https://doi.org/10.1186/s13045-020-00953-8
Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
2011 · Journal of Hematology & Oncology · 76 citations
https://doi.org/10.1186/1756-8722-4-37
Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
2018 · Blood · 38 citations
https://doi.org/10.1182/blood-2018-99-117956
BCL-2 and MYC gain/amplification is correlated with central nervous system involvement in diffuse large B cell lymphoma at leukemic phase
2017 · BMC Medical Genetics · 14 citations
https://doi.org/10.1186/s12881-017-0381-z
Cdc37 suppression induces plasma cell immaturation and bortezomib resistance in multiple myeloma via Xbp1s
2020 · Oncogenesis · 13 citations
https://doi.org/10.1038/s41389-020-0216-1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat